786 related articles for article (PubMed ID: 28820649)
1. Targets of Neuroprotection in Glaucoma.
He S; Stankowska DL; Ellis DZ; Krishnamoorthy RR; Yorio T
J Ocul Pharmacol Ther; 2018; 34(1-2):85-106. PubMed ID: 28820649
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection in glaucoma: Mechanisms beyond intraocular pressure lowering.
Tribble JR; Hui F; Quintero H; El Hajji S; Bell K; Di Polo A; Williams PA
Mol Aspects Med; 2023 Aug; 92():101193. PubMed ID: 37331129
[TBL] [Abstract][Full Text] [Related]
3. Translational Pharmacology in Glaucoma Neuroprotection.
Levin LA
Handb Exp Pharmacol; 2017; 242():209-230. PubMed ID: 27752844
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers and special features of oxidative stress in the anterior segment of the eye linked to lens cataract and the trabecular meshwork injury in primary open-angle glaucoma: challenges of dual combination therapy with N-acetylcarnosine lubricant eye drops and oral formulation of nonhydrolyzed carnosine.
Babizhayev MA
Fundam Clin Pharmacol; 2012 Feb; 26(1):86-117. PubMed ID: 21883446
[TBL] [Abstract][Full Text] [Related]
5. Disease progression and the need for neuroprotection in glaucoma management.
Varma R; Peeples P; Walt JG; Bramley TJ
Am J Manag Care; 2008 Feb; 14(1 Suppl):S15-9. PubMed ID: 18284311
[TBL] [Abstract][Full Text] [Related]
6. Management of glaucoma as a neurodegenerative disease.
Jutley G; Luk SM; Dehabadi MH; Cordeiro MF
Neurodegener Dis Manag; 2017 Apr; 7(2):157-172. PubMed ID: 28540772
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers.
Chen YS; Green CR; Danesh-Meyer HV; Rupenthal ID
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):182-93. PubMed ID: 25676338
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective Strategies in Glaucoma.
Gossman CA; Christie J; Webster MK; Linn DM; Linn CL
Curr Pharm Des; 2016; 22(14):2178-92. PubMed ID: 26818878
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection in Glaucoma: Animal Models and Clinical Trials.
Almasieh M; Levin LA
Annu Rev Vis Sci; 2017 Sep; 3():91-120. PubMed ID: 28731838
[TBL] [Abstract][Full Text] [Related]
10. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection.
Nucci C; Bari M; Spanò A; Corasaniti M; Bagetta G; Maccarrone M; Morrone LA
Prog Brain Res; 2008; 173():451-64. PubMed ID: 18929127
[TBL] [Abstract][Full Text] [Related]
11. [Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma].
Mao WM; Liu Y; Wordinger YH; Clark AF; Pang IH
Zhonghua Yan Ke Za Zhi; 2016 Jun; 52(6):471-5. PubMed ID: 27373575
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of the endothelin A (ET
McGrady NR; Minton AZ; Stankowska DL; He S; Jefferies HB; Krishnamoorthy RR
BMC Neurosci; 2017 Mar; 18(1):27. PubMed ID: 28249604
[TBL] [Abstract][Full Text] [Related]
13. Is neuroprotection a viable therapy for glaucoma?
Weinreb RN; Levin LA
Arch Ophthalmol; 1999 Nov; 117(11):1540-4. PubMed ID: 10565524
[TBL] [Abstract][Full Text] [Related]
14. Protecting the retinal neurons from glaucoma: lowering ocular pressure is not enough.
Pascale A; Drago F; Govoni S
Pharmacol Res; 2012 Jul; 66(1):19-32. PubMed ID: 22433276
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotection in glaucoma: drug-based approaches.
Cheung W; Guo L; Cordeiro MF
Optom Vis Sci; 2008 Jun; 85(6):406-16. PubMed ID: 18521010
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging medical therapies in the treatment of glaucoma.
Bagnis A; Papadia M; Scotto R; Traverso CE
Expert Opin Emerg Drugs; 2011 Jun; 16(2):293-307. PubMed ID: 21406029
[TBL] [Abstract][Full Text] [Related]
17. Primary open-angle glaucoma.
Weinreb RN; Leung CK; Crowston JG; Medeiros FA; Friedman DS; Wiggs JL; Martin KR
Nat Rev Dis Primers; 2016 Sep; 2():16067. PubMed ID: 27654570
[TBL] [Abstract][Full Text] [Related]
18. Leptin as a neuroprotective agent in glaucoma.
Gupta A
Med Hypotheses; 2013 Nov; 81(5):797-802. PubMed ID: 24035688
[TBL] [Abstract][Full Text] [Related]
19. Cytidine 5'-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma.
Gandolfi S; Marchini G; Caporossi A; Scuderi G; Tomasso L; Brunoro A
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32197303
[TBL] [Abstract][Full Text] [Related]
20. Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives.
Roberti G; Tanga L; Michelessi M; Quaranta L; Parisi V; Manni G; Oddone F
Int J Mol Sci; 2015 Nov; 16(12):28401-17. PubMed ID: 26633368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
